A retrospective review of metastatic or recurrent uterine sarcomas treated with ifosfamide and doxorubicin (IMA)

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 18, Issue 3, 2008, Pages 129-134

  Aksoy, Sercan ^a   Hizli, Deniz ^b   Sarici, Saynur ^b   Öcalan, Reyhan ^b   Köse, M Faruk ^b   Güler, Nilüfer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Etlik Maternity and Women's Health Teaching Hospital   (Turkey)

Author keywords

Chemotherapy; Doxombicin; Ifosfamide; Metastasis; Recurrent; Uterine sarcoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MESNA; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; BRAIN DISEASE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMATURIA; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UTERUS SARCOMA;

EID: 55549092461     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Kanjeekal S, Chambers A, Fung MF, et al. Systemic therapy for advanced uterine sarcoma: A systematic review of the literature. Gynecol Oncol 97:624-637, 2005.
2. Sutton G, Blessing J, Hanjani P, et al. Phase II evaluation of liposomal doxorubicin (doxil) in recurrent or advanced leiomyosarcoma of the uterus: A gynecologic oncology group study. Gynecol Oncol 96:749-752, 2005.
3. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626-632, 1983.
4. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group). Cancer 55:1648-1653, 1985.
5. Thigpen JT, Blessing JA, Orr JW, Jr., et al. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A gynecologic oncology group study. Cancer Treat Rep 70:271-274, 1986.
6. Thigpen JT, Blessing JAWilbanks GD. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase ii trial of the gynecologic oncology group. Am J Clin Oncol 9:18-20, 1986.
7. Sutton GP, Blessing JA, Barrett RJ, et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A gynecologic oncology group study. Am J Obstet Gynecol 166:556-559, 1992.
8. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A gynecologic oncology group study. Gynecol Oncol 62:226-229, 1996.
9. Sutton G, Blessing JABall H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: A gynecologic oncology group study. Gynecol Oncol 74:346-349, 1999.
10. Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: A gynecologic oncology group (gog) study. Gynecol Oncol 92:644-647, 2004.
11. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 20:2824-2831, 2002.
12. Muss HB, Bundy BN, Adcock L, et al. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the gynecologic oncology group. Am J Clin Oncol 13:32-34, 1990.
13. Slayton RE, Blessing JA, Look K, et al. A phase II clinical trial of diaziquone (azq) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A gynecologic oncology group study. Invest New Drugs 9:207-208, 1991.
14. Asbury R, Blessing JA, Smith DM, et al. Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus. A gynecologic oncology group study. Am J Clin Oncol 18:397-399, 1995.
15. Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A gynecologic oncology group study. J Clin Oncol 9:1962-1966, 1991.
16. Slayton RE, Blessing JA, Angel C, et al. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: A gynecologic oncology group study. Cancer Treat Rep 71: 1303-1304, 1987.
17. Giuntoli RL, 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89:460-469, 2003.
18. Adams SF, Hickson JA, Hutto JY, et al. Pdgfr-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol 104:524-528, 2007.
19. Raspollini MR, Susini T, Amunni G, et al. Expression and amplification of her-2/neu oncogene in uterine carcinosarcomas: A marker for potential molecularly targeted treatment? Int J Gynecol Cancer 16:416-422, 2006.
20. Livasy CA, Reading FC, Moore DT, et al. Egfr expression and her2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100:101-106, 2006.